Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation

Oncotarget

Volumn 7, Issue 14, 2016, Pages 18876-18886

  Vigneswaran, Janani ^a   Tan, Yi Hung Carol ^b   Murgu, Septimiu D ^c   Won, Brian M ^b   Patton, Kathryn Alexa ^h   Villaflor, Victoria M ^b   Hoffman, Philip C ^b   Hensing, Thomas ^b   Hogarth, D Kyle ^c   Malik, Renuka ^d   MacMahon, Heber ^e   Mueller, Jeffrey ^f   Simon, Cassie A ^d   Vigneswaran, Wickii T ^g   Wigfield, Christopher H ^g   Ferguson, Mark K ^g   Husain, Aliya N ^f   Vokes, Everett E ^b   Salgia, Ravi ⁱ  

^a BROWN UNIVERSITY   (United States)

^b SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^h DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Genetic testing; Genomic alteration; Next generation sequencing; Non small cell lung cancer

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; K RAS PROTEIN; PROTEIN RET; SCATTER FACTOR RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ALK GENE; ARTICLE; CBL GENE; EGFR GENE; ERBB2 GENE; FEMALE; FGF GENE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOUS DELETION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MET GENE; MIDDLE AGED; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; PIK3CA GENE; RAF1 GENE; RET GENE; RETROSPECTIVE STUDY; ROS1 GENE; SMOKING; ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; GENOMICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC TESTING; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PRECISION MEDICINE;

EID: 84975477659     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7739     Document Type: Article

References (29)

1. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, Melosky B, Reiman T, Romeo P, Shepherd FA, Tsao MS, Leighl NB. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol. 2011; 6:1379-1391.
2. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; 29:2121-2127.
3. CAP guideline. http://www.cap.org
4. AMP guideline. http://www.amp.org/committees/clinical_ practice/AMPclinicalpracticeguidelines.cfm
5. IASLC. https://www.iaslc.org
6. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer discovery. 2013; 3:630-635.
7. Seruga B, Sadikov A, Cazap EL, Delgado LB, Digumarti R, Leighl NB, Meshref MM, Minami H, Robinson E, Yamaguchi NH, Pyle D, Cufer T. Barriers and challenges to global clinical cancer research. Oncologist. 2014; 19:61-67.
8. Ross JS, Wang K, Elkadi OR, Tarasen A, Foulke L, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Chmielecki J, Ali SM, Elvin J, Morosini D, Miller VA, Stephens PJ. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol. 2014; 67:772-776.
9. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I, Crino L. Selumetinib plus docetaxel for KRASmutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The Lancet Oncology. 2013; 14:38-47.
10. NCCN guildline. http://www.nccn.org/professionals/physician_ gls/f_guidelines.asp
11. ASCO guideline. http://www.instituteforquality.org/practice-guidelines
12. ESMO guildline. http://www.esmo.org/Guidelines
13. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010; 28:4769-4777.
14. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8:823-859.
15. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nature communications. 2014; 5:4846.
16. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6:244-285.
17. NICE guildline. https://www.nice.org.uk/guidance
18. ACCP guildline. http://www.chestnet.org/Guidelines-and-Resources
19. Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z, Brennan T, Nahas M, Donahue A, Yelensky R, Lipson D, Sheehan CE, Boguniewicz AB, Stephens PJ, Miller VA, Ross JS. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer cytopathology. 2013; 121:688-694.
20. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Laboratory investigation; a journal of technical methods and pathology. 2003; 83:1427-1435.
21. van Eijk R, Licht J, Schrumpf M, Talebian Yazdi M, Ruano D, Forte GI, Nederlof PM, Veselic M, Rabe KF, Annema JT, Smit V, Morreau H, van Wezel T. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 2011; 6:e17791.
22. Trisolini R, Cancellieri A, Tinelli C, de Biase D, Valentini I, Casadei G, Paioli D, Ferrari F, Gordini G, Patelli M, Tallini G. Randomized Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration with and without Rapid on-Site Evaluation for Lung Cancer Genotyping. Chest. 2015; 148:1430-7.
23. Alexander Drilon LW, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Naiyer A. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Targetable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res. 2015; 21:3631-9.
24. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R. Generation of comprehensive thoracic oncology database-tool for translational research. J Vis Exp. 2011; (47).
25. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, et al. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011; 1:1-11.
26. Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG, 3rd, et al. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5).
27. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31:1023-1031.
28. Russell K, Shunyakov L, Dicke KA, Maney T, Voss A. A practical approach to aid physician interpretation of clinically targetable predictive biomarker results in a multi-platform tumor profiling service. Front Pharmacol. 2014; 5:76.
29. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, Henner WD. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn. 2011; 13:48-56.